VCM
ELAB icon

Vanguard Capital Management’s Elevai Labs ELAB Stock Holding History

Vanguard Capital Management’s Portfolio ELAB Stock Details ELAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.2K Buy
+16,672
New +$42.2K ﹤0.01% 4011

Other funds holding ELAB

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Vanguard Capital Management's ELAB Position: Q2 2026 in Review

Vanguard Capital Management opened a new position in Elevai Labs (ELAB) in Q2 2026: 16,672 shares worth $20.2K. The stake represents ﹤0.01% of the portfolio and ranks #4011 among its holdings.

9 funds tracked by Wall St. Rank hold ELAB as of Q2 2026.

  • Vanguard Capital Management held 16,672 shares of Elevai Labs worth $20.2K as of Q2 2026.
  • Elevai Labs was a new Vanguard Capital Management position in Q2 2026.
  • Elevai Labs made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #4011 holding.
  • 9 funds tracked by Wall St. Rank held Elevai Labs as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.